TICKERNERD
Menu
TECXTECXHealthcare · Biotechnology

TECX Stock Forecast: Tectonic Therapeutic, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$23

The 9 Wall Street analysts covering Tectonic Therapeutic, Inc. hold a median 12-month price target of $78 — +242.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$444.0M
Ticker Nerd rank
51 / 100
Median analyst target
$78
Analysts covering
9
Revenue$0.0
Operating income−$24.2M
Net income−$22.3M
Free cash flow−$21.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

TECX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tectonic Therapeutic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Accruals
71
Momentum
62
Revisions
61
Size
55
Quality
51
Value
49
Growth
26
Issuance
24

Volatility (78): The share price has been relatively steady.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TECX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $60Median $78High $93

The green dot is the last close — the median target sits +242.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Wells FargoMaintainsOverweight$101 → $93
26 May 2026Raymond JamesUpgradeStrong Buy$76 → $81
26 May 2026Raymond JamesUpgradeStrong Buy—
14 Apr 2026StifelInitiatesBuy—
8 Jan 2026Truist SecuritiesMaintainsBuy—
3 Sept 2025OppenheimerInitiatesOutperform—
21 July 2025Truist SecuritiesInitiatesBuy—
11 June 2025Raymond JamesReinstatesOutperform$76
6 June 2025LifeSci CapitalInitiatesOutperform—
15 May 2025MizuhoMaintainsOutperform—
21 Apr 2025MizuhoInitiatesOutperform—
21 Mar 2025Wells FargoMaintainsOverweight—
31 Jan 2025Wells FargoMaintainsOverweight—
20 Nov 2024Raymond JamesInitiatesOutperform—
12 Nov 2024Wells FargoMaintainsOverweight—
11 Nov 2024Leerink PartnersMaintainsOutperform—
22 Aug 2024Wells FargoInitiatesOverweight—
24 July 2024Leerink PartnersInitiatesOutperform—
26 June 2024Piper SandlerInitiatesOverweight—
24 June 2024TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TECX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TECX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tectonic Therapeutic, Inc. (TECX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 67% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
−2.4×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−33.8%

Higher than 26% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tectonic Therapeutic, Inc. (TECX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tectonic Therapeutic, Inc. has a market value of $444.0M and an enterprise value of $221.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.8M.

  • Diluted earnings per share, trailing twelve months: $−4.57.

  • Free cash flow in the twelve months to 30 June 2026: −$72.4M.

  • Shares outstanding: 19.2M.

  • Trailing P/E: 4.6×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tectonic Therapeutic, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

TECX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECXTectonic Therapeutic, Inc.$444.0M
51
DMACDiaMedica Therapeutics, Inc.$431.9M
50
ENTXEntera Bio Ltd.$432.9M
44
EDITEditas Medicine, Inc.$435.8M
80
OVIDOvid Therapeutics, Inc.$436.7M
64
AVIRAtea Pharmaceuticals, Inc.$413.5M
72
YDESYD Bio Ltd.$410.2M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tectonic Therapeutic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TECX news & analysis

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

GlobeNewsWire · 29 Sept 2026positive

Tectonic Therapeutic reported favorable Phase 1a topline results for TX2100, an investigational antibody targeting the APJ receptor, showing single ascending doses were generally safe and well-tolerated in healthy adult volunteers. The U.S. FDA granted Fast Track designation for TX2100 in hereditary hemorrhagic telangiectasia (HHT) and cleared the IND for a Phase 1b trial, which the company plans to initiate by year-end 2026, with a Phase 2 trial planned for early 2027.

Why it matters — The positive Phase 1a results and FDA Fast Track designation represent a milestone for TX2100, advancing Tectonic's pipeline candidate for HHT toward later-stage clinical trials.

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Tectonic Therapeutic announced that its President and CEO, Alise Reicin, MD, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event was announced in a company press release dated September 3, 2026.

Why it matters — A TECX watcher would care because leadership's participation in a major investor conference provides an opportunity for the company to communicate its clinical-stage GPCR-focused development programs to the investment community.

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

Seeking Alpha · 2 Sept 2026positive

Seeking Alpha coverage highlights Tectonic Therapeutic's TX45 trial design for CpcPH-HFpEF, noting external support from Merck's CADENCE results and promising Phase 1b hemodynamic data. The article also points to the company's cash runway through Q1 2029 and Phase 1a results for TX2100 expected by Q3 2026.

Why it matters — A TECX watcher would care because the article presents external validation and pipeline progress for TX45 and TX2100, along with a cash runway that reduces near-term financing concerns.

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 6 Aug 2026positive

Tectonic Therapeutic reported second-quarter 2026 financial results and business highlights, including completion of enrollment in the TX45 APEX Phase 2 trial in PH-HFpEF with topline results expected in early Q1 2027, an IDMC recommendation to continue that study without modification, and completion of dosing for six healthy volunteer cohorts in the TX2100 Phase 1a trial with topline results anticipated by end of Q3 2026. The company reported cash and equivalents of $227.1 million as of June 30, 2026, expected to fund operations into Q1 2029.

Why it matters — A TECX watcher would care because the update signals steady clinical progress across the TX45 and TX2100 programs and confirms the company has sufficient cash runway into Q1 2029.

FAQ

Frequently asked questions about TECX stock

What is the TECX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Tectonic Therapeutic, Inc. have a median 12-month price target of $78, with estimates ranging from $60 to $93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECX stock a buy right now?

Of the 9 analysts covering Tectonic Therapeutic, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tectonic Therapeutic, Inc. 51 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECX?

As at 8 Oct 2026, Tectonic Therapeutic, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

Will TECX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +242.9% from the last close, and Ticker Nerd's factor model ranks Tectonic Therapeutic, Inc. 51 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECX stock forecast for 2030?

No analyst covering Tectonic Therapeutic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $93 over the next 12 months.

What does Tectonic Therapeutic, Inc. do?

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors, or GPCRs.

What is the latest news on TECX?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)". Tectonic Therapeutic reported favorable Phase 1a topline results for TX2100, an investigational antibody targeting the APJ receptor, showing single ascending doses were generally safe and well-tolerated in healthy adult volunteers. The U.S. FDA granted Fast Track designation for TX2100 in hereditary hemorrhagic telangiectasia (HHT) and cleared the IND for a Phase 1b trial, which the company plans to initiate by year-end 2026, with a Phase 2 trial planned for early 2027.

Company

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors, or GPCRs. Its work centers on the GEODe platform, which is designed to support the development of GPCR-targeted biologic medicines for diseases where traditional approaches have been difficult to advance. The company’s current pipeline includes programs aimed at cardiovascular, fibrotic, and rare disease areas, including candidates such as TX45 and TX2100. Tectonic Therapeutic, Inc. operates in the broader drug discovery and biologics segment, where GPCR biology is an important but technically challenging area of therapeutic innovation. Based in Watertown, Massachusetts, the company focuses on advancing specialized protein and antibody-based medicines for current unmet medical needs.

CEO Dr. Alise S. Reicin M.D., Ph.D. · 60 employees · United States · https://tectonictx.com